DeviceSpace.com
Medical Device and Diagnostics
News & Jobs
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  
 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
 Print  Email    

Pluristem Therapeutics (PSTI)' CEO Quarterly Update


2/29/2012 9:44:43 AM

HAIFA, Israel, Feb. 29, 2012 (GLOBE NEWSWIRE) -- Dear Shareholders,

We at Pluristem have been very busy during the last few quarters in exploiting our unique competitive position in being the only company with the ability to manufacture mass quantities of cells in a three dimensional manner. This advantage has attracted the attention of pharmaceutical companies in supporting our out-license business model for our PLacental eXpanded (PLX) cells. We have made significant progress in our clinical trials' schedule in the area of peripheral artery disease (PAD) and muscle injury as well as expanded our PLX product pipeline by enhancing our activity in the area of radiation exposure. Additionally, we are on track with the build out of our new commercial grade manufacturing facility in Haifa and have substantially strengthened our management team.

Read at GlobeNewswire

 Read Article at  Related Companies  News Categories
   


ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 
    

//-->